Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24474658 | 0.81 | LMNA (0.58) | LMNAHRH3MAPK14ALDH1A1RECQL | |
| SCHEMBL28393218 | 0.81 | LMNA (0.58) | LMNAHRH3MAPK14ALDH1A1KDM4E | |
| SCHEMBL24474667 | 0.81 | LMNA (0.58) | LMNAHRH3MAPK14ALDH1A1KDM4E | |
| SCHEMBL3634873 | 0.80 | LMNA (0.56) | LMNAHRH3GRM5 | |
| SCHEMBL18926546 | 0.79 | LMNA (1.00) | LMNAHRH3ALDH1A1 | |
| SCHEMBL25747238 | 0.78 | LMNA (0.39) | LMNAMAPK14ALDH1A1RECQLKDM4E | |
| SCHEMBL996088 | 0.78 | LMNA (0.53) | LMNAHRH3MAPK14ALDH1A1RECQL | |
| SCHEMBL22422293 | 0.77 | LMNA (0.96) | LMNAHRH3ALDH1A1KDM4ETDP1 | |
| SCHEMBL16122998 | 0.77 | ACACB (0.49) | LMNAHRH3ACACBALDH1A1KDM4E | |
| SCHEMBL26668403 | 0.76 | ACACB (0.48) | LMNAHRH3ACACBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192704-A1 | MONOCARBOXYLIC ACID TRANSPORTER 4 (MCT4) MODULATORS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192704-A1 | MONOCARBOXYLIC ACID TRANSPORTER 4 (MCT4) MODULATORS AND USES THEREOF | SLC16A3, SLC16A1, SLC16A8 | LMNA 3146/4885HRH3 2977/4885MAPK14 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.